Preliminary Activity Analysis In the 22 efficacy evaluable patients with PACC mutations, enozertinib demonstrated strong systemic and CNS antitumor activity. Responses observed across a wide range of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback